ArticleEuropean journal of preventive cardiology2025
Hepcidin, incident heart failure, and cardiac dysfunction in older adults: the ARIC study.
Article in European journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Implications of ferritinophagy in cardiovascular diseases and its pharmacological modulation: underlying mechanisms and clinical translation strategies.Cellular & molecular biology letters · 2026Review
- Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025Review
- Left atrial stiffness index predicts atrial fibrillation risk in heart failure with preserved ejection fraction: a nomogram model.American journal of translational research · 2025Article
- Recent advances in the interaction of ferroptosis and immune-mediated inflammation in cardiovascular disease: mechanisms and therapeutic potential.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsHepcidin regulates plasma and tissue iron levels. We studied the association of hepcidin levels with the risk of incident heart failure (HF) and cardiac dysfunction in older adults. METHODS AND
resultsWe included adults from the ongoing, longitudinal Atherosclerosis Risk in Communities (ARIC) study, who were free from prevalent anaemia and HF at Visit 5 (2011-13) and had available hepcidin and covariate data. Associations of plasma hepcidin levels with overall adjudicated incident HF, HF with reduced ejection fraction (HFrEF), and HF with preserved ejection fraction (HFpEF) were assessed using multivariable Cox proportional hazards regression models. Cross-sectional associations of hepcidin with echocardiographic measures of cardiac structure and function were estimated using multivariable linear regression models. The mean age was 75 ± 5 years old, and 56% were women. In fully adjusted models, lower hepcidin levels were associated with a higher risk of overall incident HF [hazard ratio [HR] [95% confidence interval (CI) per 50% lower hepcidin]: 1.15 [1.05-1.26]; P = 0.003] and HFpEF [HR (95% CI): 1.25 (1.10-1.42); P = 0.001]. Plasma hepcidin level was not significantly associated with the risk of incident HFrEF [HR (95% CI): 1.08 (0.94-1.24); P = 0.30]. Lower hepcidin levels were associated with higher E wave (P = 0.046), higher E/e' ratio (P = 0.002), higher left atrial volume index (P = 0.005), and higher pulmonary artery systolic pressure (P = 0.02).
conclusionIn community-dwelling older adults without anaemia, lower plasma hepcidin levels associate with a higher risk of incident HF (particularly HFpEF) and diastolic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.